Compile Data Set for Download or QSAR
Report error Found 103 for UniProtKB: Q14957
TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557699(US11466027, Compound 1l | US11358971, Compound 1h)
Affinity DataKi:  63nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557694(US11466027, Compound 1e | US11358971, Compound 1c)
Affinity DataKi:  96nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557693(US11466027, Compound 1d | US11358971, Compound 1b)
Affinity DataKi:  140nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C(Human)
Sage Therapeutics

Curated by ChEMBL
LigandPNGBDBM50597430(Dalzanemdor | DALZANEMDOR)
Affinity DataEC50:  150nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2C receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557667(US11466027, Compound 1c | US11358971, Compound 1a)
Affinity DataKi:  170nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557701(US11466027, Compound 1n | US11358971, Compound 1j)
Affinity DataKi:  180nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM576021(US11466027, Compound 1f | (R)-2-amino-3-[(7- isopr...)
Affinity DataKi:  220nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557698(US11466027, Compound 1k | US11358971, Compound 1g)
Affinity DataKi:  220nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557702(US11466027, Compound 1o | US11358971, Compound 1k)
Affinity DataKi:  260nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM576017(US11466027, Compound 1b | (R)-2-amino-3-[(7- ethyl...)
Affinity DataKi:  270nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557697(US11466027, Compound 1i | US11358971, Compound 1f)
Affinity DataKi:  360nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C(Human)
Sage Therapeutics

Curated by ChEMBL
LigandPNGBDBM50498430(CHEMBL3594112)
Affinity DataIC50: 400nMAssay Description:Inhibition of recombinant GluN1/GluN2C receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of glutamate-evoked current by whol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/3/2020
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557703(US11466027, Compound 1p | US11358971, Compound 1l)
Affinity DataKi:  490nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557696(US11466027, Compound 1h | US11358971, Compound 1e)
Affinity DataKi:  690nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436102(CHEMBL2397256 | US10273214, Example 1180-26)
Affinity DataIC50: 800nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557695(US11466027, Compound 1g | US11358971, Compound 1d)
Affinity DataKi:  860nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM576026(US11466027, Compound 1j | (R)-2-amino-3-[(7- ethox...)
Affinity DataKi:  870nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436101(CHEMBL2397257 | US10273214, Example 1180-27)
Affinity DataIC50: 1.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436082(CHEMBL2397103 | US10273214, Example 1391)
Affinity DataIC50: 1.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436090(CHEMBL2397119 | US10273214, Example 1180-31)
Affinity DataIC50: 1.20E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50611444(CHEMBL5273123)
Affinity DataEC50:  1.90E+3nMAssay Description:Positive allosteric modulator activity at GluN2C NMDA receptor (unknown origin) expressed in CHO cells co-expressing GluN1a in the presence of L-glut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436072(CHEMBL2397211 | US10273214, Example 1426)
Affinity DataIC50: 2.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50503149(CHEMBL4464605)
Affinity DataIC50: 2.00E+3nMAssay Description:Negative allosteric modulation of GluN2C receptor (unknown origin) expressed in xenopus laevis oocytes assessed as reduction in glycine-induced chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436078(CHEMBL2397109 | US10273214, Example 1180-12)
Affinity DataIC50: 2.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436085(CHEMBL2397093 | US10273214, Example 1180-15)
Affinity DataIC50: 2.40E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50503153(CHEMBL4544421)
Affinity DataIC50: 2.60E+3nMAssay Description:Negative allosteric modulation of GluN2C receptor (unknown origin) expressed in xenopus laevis oocytes assessed as reduction in glycine-induced chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436060(CHEMBL2397100 | US10273214, Example 1390)
Affinity DataEC50:  2.70E+3nMAssay Description:Positive allosteric modulation of GluN2C receptor (unknown origin) expressed in xenopus laevis oocytes assessed as increase in glycine-induced channe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436060(CHEMBL2397100 | US10273214, Example 1390)
Affinity DataIC50: 3.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436079(CHEMBL2397108 | US10273214, Example 1180-10)
Affinity DataIC50: 3.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436067(CHEMBL2397233 | US10273214, Example 1366)
Affinity DataIC50: 3.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557700(US11466027, Compound 1m | US11358971, Compound 1i)
Affinity DataKi:  3.90E+3nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436061(CHEMBL2397099 | US10273214, Example 1368)
Affinity DataIC50: 4.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C(Human)
Sage Therapeutics

Curated by ChEMBL
LigandPNGBDBM50205849(CHEMBL3938522 | US10280165, Example 1)
Affinity DataEC50:  4.70E+3nMAssay Description:Positive allosteric modulation of GluN1/GluN2C receptor (unknown origin) assessed as increase in glutamate-induced calcium flux measured at time inte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/20/2018
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436083(CHEMBL2397097 | US10273214, Example 1425)
Affinity DataIC50: 5.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50503146(CHEMBL4447266)
Affinity DataIC50: 5.40E+3nMAssay Description:Negative allosteric modulation of GluN2C receptor (unknown origin) expressed in xenopus laevis oocytes assessed as reduction in glycine-induced chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436081(CHEMBL2397105 | US10273214, Example 1392)
Affinity DataIC50: 6.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436076(CHEMBL2397124 | US10273214, Example 1180-18)
Affinity DataIC50: 6.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50503147(CHEMBL4435232)
Affinity DataEC50:  6.60E+3nMAssay Description:Positive allosteric modulation of GluN2C receptor (unknown origin) expressed in xenopus laevis oocytes assessed as increase in glycine-induced channe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50440056(CHEMBL2333944)
Affinity DataIC50: 7.00E+3nMAssay Description:Negative allosteric modulation of GluN2C receptor (unknown origin) expressed in xenopus laevis oocytes assessed as reduction in glycine-induced chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436075(CHEMBL2397208 | US10273214, Example 1369)
Affinity DataIC50: 7.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436104(CHEMBL2397254 | US10273214, Example 1180-21)
Affinity DataIC50: 7.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50324401((E)-4-(6-Methoxy-2-(3-nitrostyryl)-4-oxoquinazolin...)
Affinity DataIC50: 7.10E+3nMAssay Description:Negative allosteric modulation of GluN2C receptor (unknown origin) expressed in xenopus laevis oocytes assessed as reduction in glycine-induced chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 1/2C/3B(Human)
H. Lundbeck

US Patent
LigandPNGBDBM575980(US11466027, Compound 1a | (R)-2-amino-3-[[7- thien...)
Affinity DataKi:  7.40E+3nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C(Human)
Sage Therapeutics

Curated by ChEMBL
LigandPNGBDBM50164398(CHEMBL3799213)
Affinity DataEC50:  7.40E+3nMAssay Description:Positive allosteric modulation of GluN1/GluN2C NMDAR (unknown origin) expressed in Dox-inducible cells by BD calcium indicator dye based-fluorescence...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436069(CHEMBL2397221 | US10273214, Example 1486)
Affinity DataIC50: 9.00E+3nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM276103(2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human GluN2C receptor by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2024
Entry Details
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM276559(US10071988, Example 499 | 2-[[1-[3-(Difluoromethox...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human GluN2C receptor by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2024
Entry Details
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50436062(CHEMBL2397252 | US10273214, Example 1180-19)
Affinity DataIC50: 1.00E+4nMAssay Description:The assay involves using a cell line that expresses the NR1 subunit together with either NR2C or NR2D. These cell lines can be prepared by transfecti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2C(Human)
Sage Therapeutics

Curated by ChEMBL
LigandPNGBDBM436689(US10617676, Example 20 | N-Cyclopropyl-2-[2-oxo-6-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Negative allosteric modulation of recombinant human GluN1a/GluN2C expressed in CHO-T-REx cells assessed as inhibition of glutamate/glycine-induced re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2C(Human)
Emory University

US Patent
LigandPNGBDBM50616996(CHEMBL5416465)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human GluN2C receptor by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2024
Entry Details
PubMed
Displayed 1 to 50 (of 103 total ) | Next | Last >>
Jump to: